Sabra Health Care Stock EBITDA
| SBC Stock | EUR 17.81 0.07 0.39% |
Sabra Health Care fundamentals help investors to digest information that contributes to Sabra Health's financial success or failures. It also enables traders to predict the movement of Sabra Stock. The fundamental analysis module provides a way to measure Sabra Health's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sabra Health stock.
Sabra |
Sabra Health Care Company EBITDA Analysis
Sabra Health's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Sabra Health EBITDA | 216.89 M |
Most of Sabra Health's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sabra Health Care is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Sabra Health Care reported earnings before interest,tax, depreciation and amortization of 216.89 M. This is 70.79% lower than that of the Real Estate sector and 67.8% lower than that of the REIT - Healthcare Facilities industry. The ebitda for all Germany stocks is 94.44% higher than that of the company.
Sabra EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sabra Health's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sabra Health could also be used in its relative valuation, which is a method of valuing Sabra Health by comparing valuation metrics of similar companies.Sabra Health is rated third in ebitda category among its peers.
Sabra Fundamentals
| Return On Equity | -0.0241 | |||
| Return On Asset | 0.0155 | |||
| Profit Margin | (0.15) % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 5.1 B | |||
| Shares Outstanding | 231.16 M | |||
| Shares Owned By Insiders | 1.35 % | |||
| Shares Owned By Institutions | 90.40 % | |||
| Price To Earning | 25.24 X | |||
| Price To Book | 0.90 X | |||
| Price To Sales | 6.70 X | |||
| Revenue | 624.81 M | |||
| Gross Profit | 372.8 M | |||
| EBITDA | 216.89 M | |||
| Net Income | (77.61 M) | |||
| Cash And Equivalents | 56.81 M | |||
| Cash Per Share | 0.32 X | |||
| Total Debt | 2.31 B | |||
| Debt To Equity | 106.60 % | |||
| Current Ratio | 5.91 X | |||
| Book Value Per Share | 13.23 X | |||
| Cash Flow From Operations | 315.73 M | |||
| Earnings Per Share | (0.33) X | |||
| Target Price | 19.14 | |||
| Number Of Employees | 42 | |||
| Beta | 1.29 | |||
| Market Capitalization | 2.59 B | |||
| Total Asset | 5.75 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.09 % | |||
| Net Asset | 5.75 B | |||
| Last Dividend Paid | 1.2 |
About Sabra Health Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sabra Health Care's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sabra Health using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sabra Health Care based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Sabra Stock
Sabra Health financial ratios help investors to determine whether Sabra Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sabra with respect to the benefits of owning Sabra Health security.